Stay Informed – Subscribe to latest updates. We promise to send only relevant and valuable emails, just insights you care about!
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors